(Dapagliflozin propanediol + metformin hydrochloride) ER is under clinical development by Yooyoung Pharm and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Dapagliflozin propanediol + metformin hydrochloride) ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Dapagliflozin propanediol + metformin hydrochloride) ER overview
Dapagliflozin propanediol and Metformin hydrochloride (Yoodapaduo XR) is a combination drug, that acts as an anti-hyperglycemic agent. It is formulated as extended-release film-coated tablets for oral route of administration. Yoodapaduo XR is indicated as an adjunct to diet and exercise therapy to improve glycemic control in adult type 2 diabetic patients for whom concomitant administration of dapagliflozin and metformin is appropriate and for the effect of dapagliflozin on the occurrence of cardiovascular events in patients with type 2 diabetes mellitus whose glycemic control is inadequate and who have established cardiovascular disease or cardiovascular risk factors.
Yooyoung Pharm overview
Yooyoung Pharm (Yooyoung) is a healthcare company that develops novel medication. The company offers prescription drugs and medical devices. Its pipeline products include Simdax for acute heart failure; YYC301 is a anti-inflammatory analgesic; YYC405 which is a anti-diabetic drug; YYC506 a hyperlipidemia combination; YYD704 a drug for alopecia. The company offers its products in the therapeutic areas such as respiratory diseases, degenerative diseases and metabolic syndromes. Yooyoung is headquartered in Seoul, South Korea.
For a complete picture of (Dapagliflozin propanediol + metformin hydrochloride) ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
